Prellis Biologics
PrivateLast Round
Series C
Aug 10, 2022
Total Funding Raised
$64.55M
Company Overview
Prellis Biologics is a biotechnology company that specializes in advanced bioprinting technology to engineer human tissues in vitro, enabling precise reproduction of the human immune response for applications such as antibody discovery and tumor-immune modeling.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, 3D Printing, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prellis Biologics Comparables
Compare Prellis Biologics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbCellera Biologics Inc. | 80% | |
| Adimab | 76% | |
| Aspect Biosystems | 76% |
Prellis Biologics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 10, 2022 | ||||
| Series B | Dec 14, 2021 | ||||
| Series A Extension | May 19, 2020 | ||||
| Series A | Jul 29, 2019 | ||||
| Seed | Sep 14, 2017 | ||||
Accelerator | May 31, 2017 |
Key People
Founding team and executive leadership
Prellis Biologics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Ventures | Series A Extension |
| 415 Ventures | Seed |
| Khosla Ventures | Series C, Series A Extension, Series A, Series B |
| WRVI Capital | Series C, Series B |
| Avidity Partners | Series C |
| Celesta Capital | Series C, Series B |
| IndieBio | Series A Extension, Series A, Seed, Series B, Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 93% MoM.
- Mar 24, 2026
Developing programs in obesity, inflammation/immunology, and oncology.
Prellis Biologics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Prellis Biologics's valuation, stock price, and market status.
Is Prellis Biologics a public or private company?
Prellis Biologics is a private company.
What is the current stock price of Prellis Biologics?
Prellis Biologics is a private company with no public stock price. No recent secondary market data is available.
How much is Prellis Biologics worth (valuation)?
Valuation information for Prellis Biologics is not publicly available.
Can I buy Prellis Biologics stock?
Prellis Biologics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Prellis Biologics's last funding round?
Prellis Biologics's most recent funding round was Series C on August 10, 2022.
Who are the main investors in Prellis Biologics?
Key investors in Prellis Biologics include Future Ventures, Khosla Ventures, WRVI Capital, Avidity Partners, Celesta Capital.
Will Prellis Biologics IPO soon?
No public IPO plans have been announced for Prellis Biologics.
How can I track Prellis Biologics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Prellis Biologics's secondary market activity and sign up for updates.